NEW ZEALAND DATA SHEET

1 PRODUCT NAME
STEROCLEAR 50 µg & 100 µg per actuation
Aqueous Nasal Suspension

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Budesonide aqueous spray 50µg and 100µg per metered actuation.
For the full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM
50 µg/actuation: An almost white opaque suspension, almost odourless. Amber glass bottle fitted with a metered pump device delivering 50 µg budesonide per actuation. Delivery of valve: 50 µl (each 50 µl contains 50 µg of budesonide).

100 µg/actuation: An almost white opaque suspension, almost odourless. Amber glass bottle fitted with a metered pump device delivering 100 µg budesonide per actuation. Delivery of valve: 50 µl (each 50 µl contains 100 µg of budesonide).

4 CLINICAL PARTICULARS
4.1 Therapeutic indications
STEROCLEAR 50 Aqueous Nasal Spray is indicated for the short-term prevention and treatment of seasonal allergic rhinitis (hayfever).

STEROCLEAR 100 Aqueous Nasal Spray is indicated for the prevention and treatment of seasonal and perennial allergic rhinitis and vasomotor rhinitis.

STEROCLEAR 100 Aqueous Nasal Spray is also indicated for the symptomatic relief of nasal polyposis.

4.2 Dose and method of administration
Dose
STEROCLEAR 50
For adults and children over 12 years:
Initially one or two sprays into each nostril twice a day (morning and night), then after 2 to 3 days, one spray into each nostril twice a day.

STEROCLEAR 100
For adults and children over 6 years:
Initially one or two sprays into each nostril in the morning, then after 2 to 3 days, one spray into each nostril in the morning.

For patients with only mild initial symptoms, a total daily dose of 200 micrograms may be sufficient. For long term treatment, the lowest dose which keeps the patient symptom-free should be used. Continuous long term use in children is not recommended.

Method of administration
Patients should be instructed in the correct use of STEROCLEAR. Patients should be informed that full response may not occur until after 2-3 days of treatment. Patients should also be advised to clear
nasal passages of secretions prior to use and not to exceed the recommended dose. In seasonal allergic rhinitis, treatment ideally should start before exposure to the allergen. Do not use for more than 6 months except on medical advice.

4.3 Contraindications
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1

Severe nasal infections, especially candidiasis.

Persons with haemorrhagic diatheses or with a history of recurrent nasal bleeding.

4.4 Special warnings and precautions for use

**Clinical Response:**
The full effect of STEROCLEAR is not achieved until at least 2 to 3 days of treatment (in rare cases not until after 2 weeks).

**Concomitant Treatment:**
Concomitant treatment may sometimes be necessary to counteract potential eye symptoms caused by the allergy.

**Concomitant Corticosteroid Therapy:**
If STEROCLEAR is prescribed for patients already using corticosteroids, care should be taken to ensure that the daily dosage of STEROCLEAR is included when determining total daily corticosteroid dose.

**Continuous, Long Term Use:**
In continuous long term treatment, care should be exercised to avoid the development of nasal mucosal atrophy. The nasal mucosa should be inspected at least twice a year.
Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and between different corticosteroid preparations. Potential systemic effects may include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).

**Severe Nasal Obstruction/Congestion:**
In some patients with severe nasal obstruction and congestion, concomitant treatment with local decongestants should be considered for 2-3 days only. The decongestant should be administered a few minutes before budesonide. Nasal polypectomy may be indicated initially for patients with nasal obstruction due to nasal polypsis.

**Visual disturbance:**
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, consider evaluating for possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
**Tuberculosis:**
Whenever corticosteroid administration is required in patients with quiescent or active tuberculosis, the therapeutic advantages should be weighed against possible undesirable effects.

**Infection:**
If infection of the respiratory tract, nasal passages or paranasal sinuses is present or occurs during administration of STEROCLEAR, adequate antibacterial therapy should be promptly instituted.

**Wound Healing:**
Because of the inhibitory effect of corticosteroids on wound healing, patients who have experienced recent nasal septal ulcers, nasal surgery or trauma should not use a nasal corticosteroid until healing has occurred.

**Reduced Liver Function:**
Reduced liver function may affect the elimination of glucocorticosteroids. The pharmacokinetics after oral ingestion of budesonide were affected by compromised liver function as evidenced by a doubled systemic availability. The relevance of this finding to intranasally administered budesonide has not been established.

**Adrenocortical Function:**
Topical corticosteroids may be absorbed in amounts that can have systemic effects. Use of higher than recommended doses may suppress HPA function. However, at recommended doses, STEROCLEAR does not cause any clinically important changes in basal cortisol levels. Similar effects have been noted with inhaled budesonide, whilst still retaining the physiological circadian rhythms of plasma cortisol. This indicates that the HPA axis suppression represents a physiological adaption in response to budesonide, not necessarily adrenal insufficiency. This is further supported by inhaled and intranasal budesonide studies, which found that, at recommended doses, there was no clinically relevant effect on the response to stimulation with ACTH (predictor for clinically manifest adrenal insufficiency).

Clinically important disturbances of the HPA axis and/or adrenal insufficiency induced by stress may be related to budesonide in specific patient populations, particularly patients administering concomitant medication metabolised by CYP3A4 (see 4.5 interaction). Monitoring for signs of adrenal dysfunction is advisable in this patient group.

**Paediatric population**
Controlled clinical studies have shown that intranasal corticosteroids may cause a reduction in growth velocity in paediatric patients. While no long term studies are available for intranasal budesonide, long term studies with inhaled budesonide have shown that adult target height is ultimately achieved.

Rare individuals may be exceptionally sensitive to intranasal corticosteroids. Height measurements (e.g. via stadiometry) should be performed to identify patients with increased sensitivity. The potential growth effects of prolonged treatment should be weighed against the clinical benefits and the availability of safe and effective non-corticosteroid alternatives. To minimize the systemic effects of intranasal corticosteroids, each patient should be titrated to his/her lowest effective dose.

The continuous long term use of budesonide nasal spray in children is not recommended due to the possibility of reduced growth velocity. Studies of children with seasonal allergic rhinitis did not extend beyond four weeks of treatment.
Safety and effectiveness of intranasal budesonide in children below 6 years of age has not been established.

Do not use STEROCLEAR 50 for children under 12 years of age without first consulting with a doctor.

If hayfever symptoms do not improve within 7 days of treatment with STEROCLEAR 50, consult with a doctor.

4.5 Interaction with other medicines and other forms of interaction
The metabolism of budesonide is primarily mediated by CYP3A, a subfamily of cytochrome P450. After oral administration of ketoconazole, a potent inhibitor of cytochrome P450 3A, the mean plasma concentration of budesonide increased by more than seven fold. Concomitant administration of other known inhibitors of this enzyme (e.g. itraconazole, clarithromycin, erythromycin) may inhibit the metabolism of, and therefore increase systemic exposure to budesonide. As a result of the CYP3A4 inhibition caused by such medications there may be an increased risk of developing Cushing’s syndrome.

Cimetidine, primarily an inhibitor of cytochrome P450 1A2, caused a slight decrease in budesonide clearance and corresponding increase in its oral bioavailability.

4.6 Fertility, pregnancy and lactation

Pregnancy
(Category A)
Results from a large prospective epidemiological study and from world-wide post marketing experience indicate that inhaled budesonide during pregnancy has no adverse effects on the health of the foetus or new born child. As with other medications the administration of budesonide during pregnancy requires that the benefits for the mother be weighed against the risks for the foetus. Intranasal glucocorticosteroids such as budesonide should be considered because of the lower systemic effects, compared to oral glucocorticosteroids.

Breastfeeding
Budesonide is excreted in breast milk. However, due to the relatively low doses used via the intranasal route the amount of budesonide present in the breast milk, if any, is likely to be low. Breastfeeding can be considered if the potential benefit outweighs any potential risks.

Fertility
No data on fertility is available

4.7 Effects on ability to drive and use machines
Not relevant

4.8 Undesirable effects
Adverse local reactions following budesonide use are mild and usually transient. Systemic side effects may occur, particularly at high doses prescribed for prolonged periods. Growth suppression has been reported in association with administration of intranasal corticosteroids, however studies with inhaled budesonide indicate that this reduction in growth velocity may be transient and that final adult height may ultimately be achieved.

Adverse events reported during studies with budesonide aqueous nasal sprays:
Common (more than 1%):
Nose and throat:
Nasal irritation, itching of throat and larynx, sore throat, dry mucous membranes, dry mouth, 
increased sputum, haemorrhagic secretion, epistaxis (nose bleeding), sneezing after spraying, nasal 
crust, sinusitis.

Respiratory:
Cough, dyspnoea.

Central Nervous System:
Headache, dizziness, tiredness.

Uncommon (less than 1%):
Nose and throat:
Strong smell of spray, bad taste, earache.

Gastrointestinal:
Loss of appetite, stomach disorder, nausea.

Skin and appendages:
Skin itching.

Central Nervous System:
Tremor, sedation.

Immune System:
Immediate and delayed hypersensitivity reactions, including urticaria, rash, dermatitis, angioedema 
and pruritus.

Rare (less than or equal to 0.2%):
Ear itching, joint aches, sexual dysfunction.
Very rare cases of ulcerations of the mucous membrane, nasal septal perforations and anaphylactic 
reactions have been reported following the use of intranasal corticosteroids.

Laboratory Variables
All changes in haematology, biochemistry and urinalysis were within the normal range and were not 
considered clinically significant.

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows 
continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are 
asked to report any suspected adverse reactions https://nzphvc.otago.ac.nz/reporting/

4.9 Overdose
Acute overdosage with STEROCLEAR, even in excessive doses, is not expected to be a clinical 
problem.

In the unlikely event of prolonged excessive use of STEROCLEAR, which could possibly lead to 
adrenal suppression, treatment should be discontinued. Overdosage may give rise to signs of
Cushing's syndrome, such as increased bodyweight, lethargy, hypertension, hirsutism, cutaneous striae, personality change, ecchymosis, oedema, polyuria and polydipsia. In severe cases, the dosage of the corticosteroid should be gradually withdrawn to prevent the possibility of adrenal failure.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Corticosteroids, ATC code: R01AD05

Mechanism of action
Budesonide is a potent non-halogenated corticosteroid. In investigations in animals and humans, budesonide has shown an advantageous ratio between topical anti-inflammatory activity and systemic glucocorticoid effect over a wide dosage range. This improved ratio is due to budesonide’s high glucocorticoid receptor affinity combined with a high first pass metabolism with short half-life. The mechanism of action of intranasally administered budesonide has not yet been completely defined; however budesonide has been shown to counteract the mainly 'IgE' mediated lung anaphylaxis in guinea-pigs.

Pre-treatment for one week with intranasal budesonide 400 micrograms daily in asymptomatic patients with seasonal rhinitis, significantly, inhibited the immediate reaction to allergen challenge.

5.2 Pharmacokinetic properties

Absorption
Due to extensive first-pass metabolism in the liver, the oral bioavailability of budesonide is low (approximately 10%). After nasal administration of a large dose (1mg) of budesonide from a metered dose aerosol the systemically available fraction is approximately 15%. Negligible biotransformation occurs in human nasal mucosa.

Distribution
The maximal plasma concentration after nasal application of 100 µg budesonide is less than 0.2 nmol/L and is reached within 45 minutes. Budesonide has a volume of distribution of approximately 3 L/kg. Plasma protein binding averages 85-90%.

Biotransformation
Budesonide is metabolised in the liver by cytochrome P450 3A to more polar metabolites with low glucocorticoid activity (i.e. 100-fold lower than the parent compound). The metabolites are inactive and excreted mainly via the kidneys. No intact budesonide has been found in the urine.

Elimination
Budesonide has a high systemic clearance (approximately 1.2L/min) and the plasma half-life of budesonide in humans after nasal inhalation is 2.9 ± 0.4 hours, and the plasma clearance of unchanged budesonide is 55.2 ± 7.8 L/h.

5.3 Preclinical safety data

Carcinogenicity/Mutagenicity
The carcinogenic potential of budesonide has been evaluated in mouse and rat at oral doses up to 200 and 50 µg/kg/day, respectively. One study indicated an increased incidence of brain gliomas in male Sprague Dawley rats given budesonide, however the results were considered equivocal.
Further studies performed in male Sprague-Dawley and Fischer rats showed that the incidence of gliomas in the budesonide-treated rats was low and did not differ from that in the reference glucocorticoid groups or the controls. It was concluded that treatment with budesonide does not increase the incidence of brain tumours in the rat. No oncogenic effect was noted in the mouse. The mutagenic potential of budesonide was evaluated in 6 different test systems. No mutagenic or clastogenic effects of budesonide were found.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Glucose (anhydrous), dispersible cellulose, potassium sorbate, disodium edetate, polysorbate, hydrochloric acid and purified water

6.2 Incompatibilities
Not applicable

6.3 Shelf life
24 months stored below 25°C

6.4 Special precautions for storage
STEROCLEAR 50 µg/dose and 100 µg/dose should be protected from the light and stored below 25°C. Do not refrigerate.
Discard 90 days after first using the spray.

6.5 Nature and contents of container <and special equipment for use, administration or implantation>
Round amber glass bottle fitted with a metering, pump and nasal applicator. The pump is fitted with a 50 µl valve and a nasal adaptor. Both dosage strengths provide 200 actuations.

6.6 Special precautions for disposal <and other handling>
No special requirements for disposal

7 MEDICINE SCHEDULE
STEROCLEAR 50: Pharmacy Medicine
STEROCLEAR 100: Prescription Medicine.

8 SPONSOR
AFT Pharmaceuticals Ltd.,
Level 1, 129 Hurstmere Road, Takapuna
AUCKLAND 0622
Telephone: 0800 423 823
Fax: 0800 423 874
Email: customer.service@aftpharm.com

9 DATE OF FIRST APPROVAL
30 November 2017

10 DATE OF REVISION OF THE TEXT
29 May 2018
## SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section</th>
<th>Date</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4</td>
<td>29 May 2018</td>
<td>Addition of visual disturbance caution in Section 4.4</td>
</tr>
</tbody>
</table>